Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesMaurizio Callari, Giampaolo Bianchini, Barbara Galbardi et al.|Nature Communications|2025Cited by 5
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.Giampaolo Bianchini, Luca Gianni, Matteo Dugo et al.|Journal of Clinical Oncology|2021Cited by 1